Business Context and Reporting Period
Company: Can-Fite Biopharma Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of July 2025 (Filing Date: July 29, 2025)
Context: The Company announced the completion of a public offering on a best efforts basis to raise capital for working capital, research and development, and clinical trials.
Key Financial Metrics and Capital Structure
Offering Details:
- Securities Sold: 1,250,000 ADSs, 7,083,333 Pre-Funded Warrants, and 16,666,666 Common Warrants.
- Offering Price: $0.60 per ADS and accompanying Common Warrant; $0.599 per Pre-Funded Warrant and accompanying Common Warrant.
- Gross Proceeds: Approximately $5.0 million.
- Net Proceeds: Approximately $4.19 million after deducting fees and expenses.
Transaction Costs:
- Placement Agent Fees: 7.0% cash placement fee, 1.0% management fee, and 7.0% Placement Agent Warrants.
- Other Expenses: Non-accountable expense allowance of $50,000, up to $100,000 for legal/out-of-pocket expenses, and $15,950 in clearing fees.
Warrant Terms:
- Pre-Funded Warrants: Immediately exercisable at $0.001 per ADS.
- Common Warrants: Immediately exercisable at $0.60 per ADS; expire two years from issuance.
- Placement Agent Warrants: Exercise price of $0.75 per ADS (125% of offering price).
Revenue, Profit, and Cash Flow: The filing text does not provide a clear value for revenue, profit, operating cash flow, margins, or existing debt levels. This document focuses solely on the capital raise transaction.
Material Changes and Restrictions
Ownership Restrictions: Holders cannot exercise warrants if the exercise would result in beneficial ownership exceeding 4.99% (or 9.99% at election) of outstanding Ordinary Shares.
Standstill and Transaction Restrictions:
- Standstill: Investor agreed to customary standstill restrictions for 90 days post-closing.
- Variable Rate Transaction Ban: Company agreed not to enter into a "variable rate transaction" for one year post-closing, subject to limited exceptions.
Guidance, Outlook, and Risks
Use of Proceeds: Funds will be used for additional working capital, funding research and development, clinical trials, and general corporate purposes.
Forward-Looking Statements and Risks:
- Closing Contingency: The offering is expected to close on or about July 29, 2025, but is subject to customary closing conditions. Failure to satisfy these conditions may prevent the offering from closing.
- Uncertainty: The Company explicitly states that forward-looking statements are not guaranteed and may not occur due to reasons beyond its control.
Investor Verification Checklist
- Verify the final closing date and confirmation of the $5.0 million gross proceeds.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific representations and indemnification clauses.
- Confirm the exact dilution impact of the 16,666,666 Common Warrants and 7,083,333 Pre-Funded Warrants on existing shareholders.
- Monitor the Company's cash runway and burn rate to assess if the $4.19 million net proceeds are sufficient for the stated clinical trial funding.
- Check for any subsequent filings regarding the exercise of Pre-Funded Warrants, which could increase share count immediately.